StudyFinder
MT2022-54 A MULTINATIONAL, MULTICENTER, DOSE ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ACTIVITY OF FP-045 IN PATIENTS WITH FANCONI ANEMIA (FuschiA Study)
Recruiting
The purpose of this research study is to determine the best dose of FP-045 for Fanconi anemia pediatric and adolescent participants. The study will look at whether the participants have any side effects and if there are any possible changes in something called “biomarkers,” which are blood proteins that will be checked to see if they change when taking FP-045 and that may indicate if FP-045 can delay or prevent disease symptoms. Every participant will receive FP-045.
Male or Female
Not specified
Inclusion Criteria:
• 3 to 25 years old
• documented Fanconi anemia by chromosome breakage analysis
• women of child-bearing potential and males required to use highly effective birth control
Exclusion Criteria:
• history of any cancer except squamous cell or basal cell carcinoma of the skin or carcinoma in situ of cervix
• myelodysplastic syndrome or acute leukemia
• history of any significant medical conditions
• history of bone marrow or stem cell transplant
• see link to clinicaltrials.gov for complete criteria
Blood Disorders, Rare Diseases
Fanconi Anemia
Meera Srikanthan - srika038@umn.edu
Meera Srikanthan
PHASE1
SITE00001887
See this study on ClinicalTrials.gov